[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-salivary-gland-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-salivary-gland-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100551754","prospective-registry-study-on-the-implementation-of-simultaneous-postoperative-radiochemotherapy-for-salivary-gland-carcinomas-of-the-head-and-neck-region-100551754",false,"NCT06464198","Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region","Inclusion Criteria:\n\n* Salivary gland carcinomas of the major and minor salivary glands of the head and neck region\n* High-grade histology\n* Successful oncological resection with curative intent\n* pT3-4 or pN1-3 or Pn1(perineural sheath infiltration) or pT1-2 with scarce or positive resection margin\n* cM0\n* Indication for postoperative combined radiochemotherapy (guideline-compliant radiochemotherapy; percutaneous radiotherapy up to a total dose of 64-72 Gy (depending on resection status), common chemotherapy regimens: Paclitaxel 135mg\u002Fm² KOF d1 and cisplatin 33mg\u002Fm² KOF d1-3, q d22 or paclitaxel 135mg\u002Fm² KOF d1, carboplatin AUC 1.5 KOF d1-3 or paclitaxel 50mg\u002Fm² KOF, carboplatin AUC2 d1,8,15, q d22 or paclitaxel 50mg\u002Fm²KOF and cisplatin 30mg\u002Fm² KOF d1,8,15, q d22, 4 cycles each).\n* Patient age ≥18 years\n* WHO performance score ≤ 1\n* Signed patient information\u002Fconsent form\n\nExclusion Criteria:\n\n* Distant metastases\n* Other cancer in the last 5 years prior to study inclusion (with the exception of: adequately treated skin cancer (except melanoma) or lentigo maligno or adequately treated carcinoma in situ, in each case without evidence of active disease).\n* Previous chemotherapy or radiotherapy for salivary gland carcinoma\n* Previous radiotherapy in the head and neck area\n* Pre-existing uncontrolled disease that constitutes a contraindication to simultaneous combination chemotherapy (e.g. signs of acute heart failure, myocardial infarction within the last 6 months before the start of therapy, congestive heart failure, heart disease with New York Heart Association (NYHA) III or IV classification, active and therapy-resistant infection, pre-existing or concomitant immunodeficiency syndrome)\n* Pregnancy and breastfeeding\n* Fertile patients who cannot ensure effective contraception during and up to six months after combination therapy","ALL","18 Years","99 Years",{"count":19,"type":20},100,"ESTIMATED","5 Years","OBSERVATIONAL","This is a prospective registry study based on a standard therapy concept for postoperative simultaneous radiochemotherapy established in Erlangen and elsewhere. The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated. Patients with locally advanced high-grade salivary gland carcinoma after oncological resection are admitted.",[25],"Locally Advanced Salivary Gland Carcinoma","RECRUITING","2026-03-11",{"date":29,"type":30},"2026-03-13","ACTUAL",{"date":32,"type":30},"2024-06-01",{"date":34,"type":20},"2037-06",{"name":36,"class":37},"University of Erlangen-Nürnberg Medical School","OTHER"]